Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Receptor Decoy Peptide Lowers Blood Pressure | LifeTein Peptide Blog

Adult type 2 diabetics are at very high risk of obesity-associated hypertension, where the end result can be as grave as heart failure. The systems involved in the human body regarding these conditions can be complex, but scientists have identified cases of st

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Adult type 2 diabetics are at very high risk of obesity-associated hypertension, where the end result can be as grave as heart failure. The systems involved in the human body regarding these conditions can be complex, but scientists have identified cases of stroke and refractory hypertension that harbored increased plasma IgG, 5-hydroxytryptamine 2A receptor (5-HT2AR)-targeting autoantibodies. Serotonin 2A-Receptor Decoy Peptide Lowers Blood PressureThe goal was to test whether a decoy receptor peptide could lower blood pressure in an animal model of obesity-associated hypertension. The team developed the decoy receptor peptide, SCLLADDN (Sertuercept), and LifeTein synthesized it successfully for the project. Using Zucker hypertensive diabetic fatty rats as the model, the team proved their theory.Results showed after implementing the decoy receptor peptide, acute and long-lasting significant systolic and diastolic blood pressure-lowering occurred within the rat models. This followed through without any long-term side effects after chronic administration. Hopefully, these results are fruitful in later applications and the same peptide can be used to help significantly lower blood pressure in humans afflicted with type 2 diabetes as well. Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinology, Diabetes and Metabolism Journal. 2021 Aug;5(2). DOI: 10.31038/edmj.2021523. PMID: 35035793; PMCID: PMC8759716.

A linear synthetic peptide, SCLLADDN (SN..8 or P4) having a sequenceidentical to that of a fragment of the second extracellular loop region of the human 5-hydroxytryptamine 2A receptor was synthesized at Lifetein, Inc (Hillsborough, NJ) andhad > 95% purity. Substitutions of SCLLADDN containing a single alanine amino acidreplacement, e.g. SALLADDN, SCLLADAN were synthesized at Lifetein, Inc (Hillsborough,NJ) and had purity of > 95%.

Grinberg, M.; Burton, J.; Pang, K.C.; Zimering, M.B. Neuroprotective Effects of a Serotonin Receptor Peptide Follow-ing Sham vs. Mild Traumatic Brain Injury in the Zucker Rat. Preprints 2023, 2023050004. https://doi.org/10.20944/preprints202305.0004.v1

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Clinical Trials and Research

Several clinical trials have explored the use of PADRE in cancer vaccines. For instance, vaccines targeting Mucin 1 (MUC1), a glycoprotein overexpressed in many cancers, have shown promising results when combined with PADRE. These vaccines have demonstrated the ability to elicit strong immune responses, including the production of antibodies against cancer-specific antigens.

Source: lifetein.com ↗

Protein-Protein Interaction Studies

In FRET-based assays, TAMRA acts as an acceptor dye paired with donors like fluorescein. This configuration allows detection of molecular interactions between labeled peptides and target proteins. For instance, TAMRA-labeled kinase substrate peptides can reveal enzymatic activity by quantifying changes in FRET efficiency upon phosphorylation. Find other fluorescent pairs here.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Conformational Stability and Target Interactions

Acetylation often stabilizes α-helical or turn structures near the N-terminus, optimizing receptor-binding interfaces. However, this benefit is sequence-dependent: acetylation may disrupt activity if the N-terminus participates directly in target engagement.

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides